ALLK Logo

Allakos Inc. (ALLK) 

NASDAQ
Market Cap
$107.21M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
527 of 960
Rank in Industry
287 of 550

Largest Insider Buys in Sector

ALLK Stock Price History Chart

ALLK Stock Performance

About Allakos Inc.

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab …

Insider Activity of Allakos Inc.

Over the last 12 months, insiders at Allakos Inc. have bought $0 and sold $87,935 worth of Allakos Inc. stock.

On average, over the past 5 years, insiders at Allakos Inc. have bought $0 and sold $142.03M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 222,222 shares for transaction amount of $4M was made by MCKEARN JOHN P () on 2018‑07‑23.

List of Insider Buy and Sell Transactions, Allakos Inc.

2024-06-28SaleChief Financial Officer
87,064
0.0937%
$1.01$87,9350.00%
2021-09-28Saledirector
4,000
0.0075%
$108.12$432,480-94.75%
2021-06-14SalePresident and COO
20,000
0.0376%
$91.62$1.83M-15.78%
2021-06-07SalePresident and COO
2,487
0.0047%
$92.03$228,879-14.19%
2021-06-04SaleChief Executive Officer
23,595
0.044%
$89.64$2.11M-12.39%
2021-06-04SalePresident and COO
642
0.0012%
$90.26$57,947-12.39%
2021-06-04SaleChief Medical Officer
2,435
0.0045%
$89.60$218,176-12.39%
2021-06-03SaleChief Executive Officer
20,001
0.0378%
$92.13$1.84M-13.45%
2021-06-02SaleChief Executive Officer
20,001
0.0369%
$94.55$1.89M-17.34%
2021-05-19SaleChief Executive Officer
19,998
0.0374%
$98.93$1.98M-18.90%
2021-05-18SaleChief Executive Officer
20,001
0.0377%
$102.31$2.05M-20.84%
2021-05-17SaleChief Executive Officer
20,001
0.0369%
$99.68$1.99M-20.43%
2021-05-10SalePresident and COO
20,000
0.0377%
$96.02$1.92M-14.94%
2021-04-14SalePresident, COO and CFO
20,000
0.0373%
$107.77$2.16M-23.40%
2021-04-13SalePresident, COO and CFO
20,000
0.0368%
$103.08$2.06M-21.06%
2021-04-12SalePresident, COO and CFO
20,000
0.0373%
$104.40$2.09M-20.99%
2021-04-06SaleChief Medical Officer
10,000
0.0189%
$111.68$1.12M-24.45%
2021-04-05SaleChief Medical Officer
20,000
0.0374%
$113.06$2.26M-26.01%
2021-04-01SaleChief Medical Officer
20,000
0.0374%
$114.40$2.29M-26.91%
2021-03-26Sale
17,308
0.0325%
$115.17$1.99M-26.70%

Insider Historical Profitability

13.36%
Alta Partners VIII, L.P.10 percent owner
11519200
12.8931%
$1.2010+13.36%
RiverVest Venture Fund III, L.P.10 percent owner
5750506
6.4364%
$1.20114+13.36%
JANNEY DANIEL
56293
0.063%
$1.2016+13.36%
MCKEARN JOHN Pdirector
1200
0.0013%
$1.20115+13.36%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Bvf Inc Il$20.86M18.6916.55M+93.54%+$10.08M0.15
Nea Management Company Llc$7.75M6.946.15M0%+$00.04
Deep Track Capital Lp$6.3M5.655M+99.14%+$3.14M0.03
BlackRock$5.95M5.334.72M-7.73%-$498,099.38<0.0001
The Vanguard Group$4.78M4.293.79M+16.56%+$679,249.54<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.